APP and Down syndrome: Other studies have shown that plasma Aβ42 concentrations increased prior to dementia onset in familial AD with presenilin or amyloid precursor protein (APP) mutations44,45, in Down syndrome with APP triplication46,47, and in first-degree relatives of AD patients, who are at an increased risk of developing the disease48–50.